Compositions of multiple nucleic acid vectors and uses thereof
By introducing IIS type restriction endonuclease cleavage sites and methylation hindering mechanisms into the vector, the problems of low efficiency and high noise in cloning technology are solved, and efficient polynucleic acid assembly and predetermined sequence formation are achieved.
Patent Information
- Application Number
- CN202080018559.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-01-09
- Filing Date
- 2020-01-07
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-01-07
AI Technical Summary
The existing cloning technology has problems such as inefficient and requires restriction endonuclease cleavage site selection and scar introduction during the insertion of nucleic acid fragments into the vector. The background noise is high during the cloning process, making it difficult to achieve efficient Polynucleic acid assembly.
The target vector and entry vector containing the IIS restriction endonuclease cleavage site are used to generate polynucleic acid fragments through the methylation hindering mechanism, and cleavage and ligation are used to use the IIS restriction endonuclease to form a predetermined The cyclic polynucleic acid of the sequence.
The efficiency of the cloning process is improved, background noise is reduced, dependence on restriction endonucleases and selection mechanisms is eliminated, and efficient polynucleic acid assembly and the formation of predetermined sequences is achieved.
Smart Images

Figure CN113544274B_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Application Serial No. 62 / 790,343, filed on January 9, 2019, the entire contents of which are incorporated herein by reference. Technical Field
[0003] Compositions of destination vectors and entry vectors are disclosed herein. Also disclosed herein are uses of destination vectors and entry vectors in methylation-hindered assembly reactions, wherein the assembled sequence can be used as an entry vector in a subsequent assembly reaction. Background Art
[0004] Various cloning strategies have been described previously. Traditionally, restriction ligation cloning is used to insert a nucleic acid fragment of interest into a vector. Because of the limitations of this traditional method, such as those associated with restriction endonuclease cleavage sites, the introduction of "scars", the selection of restriction endonucleases, and the low efficiency of cloning, other methods have been developed to clone larger polynucleic acids in a hierarchical manner. For example, IIS-type hierarchical cloning strategies include MoClo (Addgene) and Golden Gate (NEB), and recombination-based hierarchical cloning strategies include Gateway Cloning (Thermo). Summary of the invention
[0005] In some aspects, the present disclosure relates to a destination vector. In some embodiments, a polynucleic acid destination vector comprises a backbone component and an insertion site component, wherein: (a) the backbone component comprises a nucleic acid sequence of a selectable marker, an origin of replication, and at least one IIS type restriction enzyme cleavage site comprising a common recognition site and a corresponding cleavage site, wherein the common recognition site overlaps with a methylation site; and (b) the insertion site component comprises a 5' IIS type double restriction enzyme cleavage site and a 3' IIS type double restriction enzyme cleavage site, optionally, wherein the 5' IIS type double restriction enzyme cleavage site and the 3' IIS type double restriction enzyme cleavage site are separated by at least one nucleotide; wherein each IIS type double restriction enzyme cleavage site comprises: (i) a first common recognition site and a corresponding cleavage site, wherein the first common recognition site overlaps with a methylation site forming a boundary between the insertion site component and the backbone component, and (ii) a second common recognition site and a corresponding cleavage site, wherein the second recognition site lacks an overlapping methylation site, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site are both located between the first common recognition site and the second common recognition site, wherein: methylation of the target vector at the common recognition site overlapping with the methylation site hinders cleavage of the cleavage site corresponding to the common recognition site; when methylated, the target vector is exposed to an IIS type restriction endonuclease that recognizes the common recognition site of the target vector, generating two polynucleic acid fragments, wherein the nucleotide sequences of the 5' end nucleic acid protrusion or the 3' end nucleic acid protrusion of the fragment including the backbone component are different; and the nucleotide sequence of the IIS type cleavage site in (a) is different from that of the IIS type cleavage site in (b).
[0006] In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction site or the 3' IIS type double restriction site are separated by at least one nucleotide. In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction site and the 3' IIS type double restriction site are separated from each other by at least one nucleotide.
[0007] In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5'IIS type double restriction enzyme site and the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 3'IIS type double restriction enzyme site are separated from each other by different nucleotide sequences. In some embodiments, the different nucleotide sequences include different nucleic acid lengths.
[0008] In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction enzyme cleavage site and the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 3' IIS type double restriction enzyme cleavage site are separated from each other by the same nucleotide sequence.
[0009] In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction enzyme cleavage site and / or the 3' IIS type double restriction enzyme cleavage site are shared cleavage sites.
[0010] In some embodiments, the 5' IIS type double restriction site and the 3' IIS type double restriction site are separated by a nucleic acid sequence encoding a visual readout marker or a suicide box. In some embodiments, the visual readout marker is selected from the group consisting of: a fluorescent protein, a chromogenic protein, LacZ or LacZα. In some embodiments, the suicide box includes a nucleic acid sequence of ccdB.
[0011] In some embodiments, the IIS type restriction endonuclease that binds to the common recognition site is selected from the group consisting of: BsaI, BsmBI, BtgZI, Esp3I, FokI, HphI, BcgI, AlwI, MboII, MmeI, BsmFI, BceAI, BcoDI, BfuAI, BsmAI, EarI, EciI, FauI, HgaI, HpyAV, PleI, BbsI, SapI and SfaNI. In some embodiments, the IIS type restriction endonuclease is a high-fidelity restriction endonuclease. In some embodiments, at least one IIS type restriction enzyme cutting site in the backbone component of (a) is located within or flanking a selection marker or a replication origin. In some embodiments, the cleavage site of at least one IIS type restriction enzyme cutting site in the backbone component of (a) includes a low ligation efficiency sequence content. In some embodiments, the selection marker includes an antibiotic resistance gene.
[0012] In some embodiments, the methylation sites of (a) and (b) are methylated by the same methyltransferase.
[0013] In some embodiments, the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase and TaqI methyltransferase.
[0014] In some embodiments, when unmethylated, exposing the target vector to a Type IIS restriction endonuclease that recognizes a common recognition site of the target vector generates at least three polynucleic acid fragments, wherein each polynucleic acid includes a 5' nucleic acid overhang or a 3' nucleic acid overhang, and the nucleotide sequences of the 5' nucleic acid overhang or the 3' nucleic acid overhang of the fragments including the second common recognition sequence of the 5' Type IIS double restriction enzyme site and the 3' Type IIS double restriction enzyme site are different.
[0015] In other aspects, the present disclosure relates to entry vectors. In some embodiments, the polynucleic acid entry vector includes a backbone component and an insertion component, wherein (a) the backbone component includes a backbone component of a polynucleic acid destination vector as disclosed herein; (b) the insertion component includes a first IIS type restriction site, an insertion sequence, and a second IIS type restriction site from 5' to 3'; wherein the first IIS type restriction site and the second IIS type restriction site each include: (i) a common recognition site overlapping with a methylation site, wherein the methylation site forms a boundary between the insertion component and the backbone component, and (ii) a corresponding cleavage site, wherein the cleavage of the cleavage site of the first IIS type restriction site and the second IIS type restriction site generates a 5' overhang or a 3' overhang, wherein the nucleotide sequences of the 5' overhang or the 3' overhang of the first IIS type restriction site and the 5' overhang or the 3' overhang of the second IIS type restriction site are different from each other. In some embodiments, the insertion sequence is a nucleic acid sequence combined in an assembly reaction.
[0016] In still other aspects, the present disclosure relates to methods for assembling polynucleic acids into a predetermined sequence. In some embodiments, the method comprises: (a) forming a reaction mixture by combining: (i) a destination vector as disclosed herein, wherein the methylation sites of both the backbone component and the insertion site component of the destination vector are methylated; (ii) at least one entry vector as disclosed herein, wherein the methylation sites of the backbone component and the insertion component of each of at least one entry vector are unmethylated; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes a common recognition site of the destination vector and the entry vector; and (iv) a ligase; (b) incubating the reaction mixture for a sufficient period of time for the destination vector to be ligated. (c) incubating the reaction mixture for a time sufficient for a ligase to ligate the insert sequence of each of the at least one entry vector into the backbone component of the destination vector, thereby generating a circular polynucleic acid; and wherein the 5' overhang or 3' overhang of the backbone component of the destination vector and the insert component of each of the at least one entry vector are uniquely complementary to each other so as to form a predetermined sequence comprising the backbone component of the destination vector of step (a)(i) and the insert component of each of the at least one entry vector of step (a)(ii).
[0017] In some embodiments, the destination vector is methylated in vitro. In some embodiments, the destination vector is methylated in vivo. In some embodiments, the destination vector is methylated in a bacterial strain expressing a methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase and TaqI methyltransferase.
[0018] In some embodiments, the method further comprises separating the ligated destination vector containing the insert sequence from the other components of the reaction mixture. In some embodiments, the ligated destination vector is separated by transforming bacteria with the reaction mixture and screening bacteria for the presence of correctly ligated assemblies.
[0019] In some embodiments, the method further comprises demethylating the separated ligated destination vector to generate a second entry vector. In some embodiments, the separated ligated destination vector is passively demethylated in vivo by replication in a bacterial strain lacking a methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
[0020] In other aspects, the present disclosure relates to methods of cloning a nucleic acid sequence of interest. In some embodiments, the method includes: (a) forming a reaction mixture by combining the following: (i) a destination vector as disclosed herein, wherein the methylation site of the backbone component is methylated; (ii) at least one polynucleic acid fragment, wherein each polynucleic acid fragment includes an internal sequence, wherein the internal sequence is flanked at both ends by a common recognition site and a corresponding cleavage site; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes the common recognition site of the destination vector and the at least one polynucleic acid fragment; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for the Type IIS restriction endonuclease-mediated cleavage of the destination vector and the at least one polynucleic acid fragment; and (c) incubating the reaction mixture for a time sufficient for the ligase to ligate the internal nucleic acid sequence of each of the at least one polynucleic acid fragment to the backbone component of the destination vector, thereby generating a circular polynucleic acid; and wherein the internal sequence of at least one polynucleic acid fragment includes a nucleic acid sequence of interest; and wherein the 5' overhang or 3' overhang of the backbone component of the destination vector and each internal sequence of the at least one polynucleic acid fragment are uniquely complementary to each other so as to form a predetermined sequence comprising the backbone component of the destination vector of step (a)(i) and the nucleic acid sequence of interest.
[0021] In some embodiments, the destination vector is methylated in vitro. In some embodiments, the destination vector is methylated in vivo. In some embodiments, the destination vector is methylated in a bacterial strain expressing a methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase and TaqI methyltransferase.
[0022] In some embodiments, the method further comprises separating the ligated destination vector containing the insert sequence from the other components of the reaction mixture. In some embodiments, the ligated destination vector is separated by transforming bacteria with the reaction mixture and screening bacteria for the presence of correctly ligated assemblies.
[0023] In some embodiments, the method further comprises demethylating the separated ligated destination vector to generate a second entry vector. In some embodiments, the separated ligated destination vector is passively demethylated in vivo by replication in a bacterial strain lacking a methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
[0024] In other embodiments, the method includes: (a) forming a reaction mixture by combining the following: (i) at least one entry vector as disclosed herein, wherein the methylation sites of the backbone component are unmethylated; (ii) polynucleic acid fragments, wherein the polynucleic acid fragments include internal sequences, wherein the internal sequences are flanked at both ends by a common recognition site and a corresponding cleavage site; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes the common recognition site of at least one entry vector and the polynucleic acid fragment; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for Type IIS restriction endonuclease-mediated cleavage of at least one entry vector and the polynucleic acid fragment; and (c) incubating the reaction mixture for a time sufficient for the ligase to connect the internal nucleic acid sequence of the polynucleic acid fragment to the insertion component of each of the at least one entry vector, thereby generating a circular polynucleic acid; and wherein the internal sequence of the polynucleic acid fragment includes a selection marker and an origin of replication; and wherein the 5' overhang or 3' overhang of the insertion component of each of the at least one entry vector and the internal sequence of the at least one polynucleic acid fragment are uniquely complementary to each other so as to form a predetermined sequence including the nucleic acid sequence of interest.
[0025] In some embodiments, the multiple nucleic acid fragments are PCR products.
[0026] In some embodiments, the polynucleic acid fragments are methylated in vitro.
[0027] In some embodiments, the predetermined sequence further comprises a sequence entering the vector. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The following drawings form part of this specification and are included to further illustrate certain aspects of the present disclosure, which may be better understood by reference to one or more of these drawings in conjunction with the detailed description of specific embodiments presented herein. It should be understood that the data illustrated in the drawings in no way limit the scope of the present disclosure.
[0029] Figure 1 An embodiment of a destination vector is schematically depicted. The nucleic acid sequence of the 5' IIS type restriction site is CCGGTCTCNNNNNNGAGACC (SEQ ID NO: 1), and the nucleic acid sequence of the 3' IIS type restriction site is GGTCTCNNNNNNGAGACCGG (SEQ ID NO: 2), wherein N represents A, T, G or C.
[0030] Figure 2 An embodiment of an entry vector is schematically depicted. The nucleic acid sequence of the first Type IIS restriction site is CCGGTCTCNNNNNN (SEQ ID NO: 3), and the nucleic acid sequence of the second Type IIS restriction site is NNNNNGAGACCGG (SEQ ID NO: 4), wherein N represents A, T, G or C.
[0031] Figure 3 Schematic depiction of an embodiment of a methylation-hindered assembly reaction. Figure 1 and Figure 2 Mark in. DETAILED DESCRIPTION
[0032] Disclosed herein are compositions of destination vectors and entry vectors, and compositions of kits for assembling polynucleic acids with predetermined sequences. Also disclosed herein are methods for assembling polynucleic acids with predetermined sequences, including assembly reactions hindered by methylation, wherein the assembled predetermined sequences can be used as entry vectors for subsequent assembly reactions. These compositions and methods are based on the previously described hierarchical cloning strategies. In particular, the disclosed compositions and methods can eliminate the need for switching restriction endonucleases and / or selected mechanisms between cloning stages. Moreover, the disclosed methods can exhibit reduced background because the backbone of the donor vector can be degraded during the cloning process.
[0033] Target vector and composition
[0034] In some aspects, the present disclosure relates to a destination vector polynucleic acid and a composition comprising a destination vector polynucleic acid. In some embodiments, the destination vector is a linear vector. In other embodiments, the destination vector is a circular vector. The destination vector includes a backbone component and an insertion site component.
[0035] As used herein, the term "backbone component" refers to the portion of the destination vector flanking the insertion component (or the portion of the entry vector flanking the insertion component, see "Entry Vectors and Compositions" below) and includes at least one origin of replication. In some embodiments, the backbone component further includes a selectable marker gene.
[0036] In some embodiments, the selectable marker comprises a visible readout gene, such as a fluorescent protein or a chromogenic protein. Examples of fluorescent proteins are known to those skilled in the art and include, but are not limited to, TagBFP, mTagBFP2, Azurite, EBFP2, mKalama1, Sirius, Sapphire, T-Sapphire, ECFP, Cerulean, SCFP3A, mTurquoise, mTurquoise2, monomeric Midoriishi-Cyan, TagCFP, mTFP1, EGFP, Emerald, SuperfolderGFP, Monomeric Azami Green, TagGFP2, mUKG, mWasabi, Clover, mNeonGreen, EYFP, Citrine, Venus, SYFP2, TagYFP, Monomeric Kusabira-Orange, mKOκ, mKOO mOrange2, mRaspberry, mCherry, mStrawberry, mTangerine, tdTomato, TagRFP, TagRFP-T, mApple, mRuby, mRuby2, mPlum, HcRed-Tandem, mKate2, mNeptune, NirFP, TagRFP657, IFP1.4 and iRFP. The example of chromogenic protein is known to those of ordinary skill in the art. See, for example, U.S. Patent No. 9,771,402 (describing various chromogenic proteins). In some embodiments, selective markers include auxotrophic complement genes. In some embodiments, selective markers include antibiotic resistance genes. The example of selective markers is known to those skilled in the art and includes but is not limited to AmpR, NeoR, mFabI, ZeoR, NAT, HygR, SpcR (AadA), Pac, Ura3, His3, Leu2 and Trp1.
[0037] In some embodiments, the backbone component further comprises at least one Type IIS restriction site.
[0038] As used herein, the term "restriction site" refers to a polynucleotide sequence comprising a recognition site and a corresponding cleavage site. As used herein, the term "recognition site" refers to a polynucleotide sequence that is recognized by and specifically binds to an IIS type restriction endonuclease. A "corresponding cleavage site" refers to a site that is cleaved when an IIS type restriction endonuclease binds to the recognition site. In some embodiments, the cleavage site is only two nucleotides in length, and cleavage occurs between the two nucleotides (corresponding to a blunt-ended cleavage site). In some embodiments, the length of the cleavage site is at least 3 nucleotides (corresponding to the 5' overhang site or 3' overhang site of a single-stranded overhang including at least 1 nucleotide), at least 4 nucleotides (corresponding to the 5' overhang site or 3' overhang site of a single-stranded overhang including at least 2 nucleotides), at least 5 nucleotides (corresponding to the 5' overhang site or 3' overhang site of a single-stranded overhang including at least 3 nucleotides), at least 6 nucleotides (corresponding to the 5' overhang site or 3' overhang site of a single-stranded overhang including at least 4 nucleotides), at least 7 nucleotides (corresponding to the 5' overhang site or 3' overhang site of a single-stranded overhang including at least 5 nucleotides), at least 8 nucleotides (corresponding to the 5' overhang site or 3' overhang site of a single-stranded overhang including at least 6 nucleotides) or at least 9 nucleotides (corresponding to the 5' overhang site or 3' overhang site of a single-stranded overhang including at least 7 nucleotides). In some embodiments, cleavage of the cleavage site generates a single-stranded overhang. The length of the overhang can vary (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 nucleotides in length). In some embodiments, the overhang is a 5' overhang. In other embodiments, the overhang is a 3' overhang.
[0039] IIS type restriction endonucleases recognize asymmetric DNA sequences and cut outside their recognition sequences. Examples of known IIS type restriction endonucleases include, but are not limited to, AcuI, AlwI, BaeI, BbsI, BbvI, BccI, BceAI, BcgI, BciVI, BcoDI, BfuAI, BmrI, BpmI, BpuEI, BsaI, BsaXI, BseRI, BsgI, BsmAI, BsmBI, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BtsI, BtsIMutI, CspCI, EarI, EciI, Esp3I, FauI, FokI, HgaI, MphI, HgaI, MphI MnII, NmeAIII, PleI, SapI, and SfaNI. In some embodiments, the Type IIS restriction endonuclease is a high-fidelity restriction endonuclease.
[0040] Some type IIS restriction endonucleases are sensitive to methylation and include, but are not limited to, AlwI (dam methylation sensitive), BceAI (CpG methylation sensitive), BcgI (dam and CpG methylation sensitive), BcoDI (CpG methylation sensitive), BfuAI (CpG methylation sensitive), BsaI (dcm and CpG methylation sensitive), BsmAI (CpG methylation sensitive), BsmBI (CpG methylation sensitive), BsmFI (dcm and CpG methylation sensitive), BtgZI (CpG methylation sensitive), EarI ( CpG methylation sensitive), EciI (CpG methylation sensitive), Esp3I (CpG methylation sensitive), FauI (CpG methylation sensitive), FokI (dcm and CpG methylation sensitive), HgaI (CpG methylation sensitive), HphI (dam and dcm methylation sensitive), HpyAV (CpG methylation sensitive), MboII (dam methylation sensitive), MmeI (CpG methylation sensitive), SapI (CpG methylation sensitive), PleI (CpG methylation sensitive), and SfaNI (CpG methylation sensitive).
[0041] In some embodiments, the recognition site is a common recognition site. Each "common recognition site" in the destination vector (or the entry vector described in "entry vector and composition" below): (i) composed of the same nucleotide sequence and / or (ii) including the nucleotide sequence (some IIS type restriction endonucleases recognize various sequences) recognized and combined by the same IIS type restriction endonuclease; For example, MmeI, its recognition sequence 5'-TCCRAC-3', wherein R represents A or G). In some embodiments, at least one common recognition site of the backbone component overlaps with the methylation site (that is, the sequence recognized and methylated by methyltransferase, such as CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase and TaqI methyltransferase). In some embodiments, the methylation sites include dcm, dam and / or CpG methylation sites.
[0042] In some embodiments, the Type IIS restriction endonuclease that binds to a common recognition site is selected from the group consisting of Acul, AlwI, BaeI, BbsI, BbvI, BccI, BceAI, BcgI, BciVI, BcoDI, BfuAI, BmrI, BpmI, BpuEI, BsaI, BsaXI, BseRI, BsgI, BsmAI, BsmBI, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BtsI, BtsIMutI, CspCI, EarI, Eciga, FII, HII, HpyAV, MboII, MlyI, MmeI, MnII, NmeAIII, PleI, SapI, and SfaNI. In some embodiments, the IIS type restriction endonuclease that binds to the common recognition site is a methylation-sensitive restriction endonuclease selected from the group consisting of: AlwI, BceAI, BcgI, BcoDI, BfuAI, BsaI, BsmAI, BsmBI, BsmFI, BtgZI, EarI, EciI, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, MboII, MmeI, PleI, SapI, and SfaNI. The methylation-sensitive restriction endonuclease will not cut the cleavage site corresponding to the methylation recognition site.
[0043] In some embodiments, at least one Type IIS restriction site is located within or flanking the selectable marker and / or origin of replication of the backbone component.
[0044] In some embodiments, the backbone component comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 or more than 10 Type IIS restriction sites. In some embodiments, at least 2 Type IIS restriction sites of the backbone component comprise a common recognition site. In some embodiments, each of the at least 2 common recognition sites of the backbone component flanks a methylation site.
[0045] In some embodiments, the cleavage site of at least one IIS type restriction enzyme cleavage site (e.g., a cleavage site corresponding to a common recognition site) in the backbone component includes a low ligation efficiency sequence content. For example, in some embodiments, the low ligation efficiency sequence includes a blunt end cleavage site. In other embodiments, the low ligation efficiency sequence includes an overhang of two or fewer nucleotides. Other examples of low efficiency ligation sequences are known in the art and include, but are not limited to, TNNA, TTTT, and AAAA. See, e.g., Potapov V. et al., A single-molecule sequencing assay for the comprehensive profiling of T4 DNA ligase fidelity and bias during DNA end-joining. Nucleic Acids Res. 2018 Jul 27; 46(13): e79; Vladimir P. et al., Optimization of Golden Gate assembly through application of ligation sequence-dependent fidelity and bias profiling. BioRxiv. 2018 May 15; doi10.1101 / 322297, which are incorporated herein in their entirety.
[0046] As used herein, the term "insertion site component" refers to a polynucleic acid that includes a 5' Type IIS double restriction site and a 3' Type IIS double restriction site (see, e.g., Figure 1). As used herein, the term "double restriction site" refers to a nucleic acid sequence comprising a pair of inwardly facing IIS type restriction sites (i.e., the cleavage sites corresponding to each recognition site - the first recognition site and the second recognition site are located between the two recognition sites). In some embodiments, the nucleic acid sequence of the 3'IIS type double restriction site is the reverse complement of the 5'IIS type double restriction site, except for the nucleic acid sequence of one or more cleavage sites. For example, in some embodiments, the nucleic acid sequence of the 5'IIS type double restriction site is CCGGTCTCNNNNNNGAGACC (SEQ ID NO: 1), and the nucleic acid sequence of the 3'IIS type double restriction site is GGTCTCNNNNNNGAGACCGG (SEQ ID NO: 2), wherein N represents A, T, G or C.
[0047] In some embodiments, the first recognition site and / or the second recognition site of the double restriction enzyme site are common recognition sites. In some embodiments, the common recognition site of the double restriction enzyme site overlaps with a methylation site (i.e., a sequence recognized and methylated by a methyltransferase). In some embodiments, the methylation site includes dcm, dam and / or CpG methylation sites.
[0048] In some embodiments, the double restriction enzyme cutting site comprises: (i) a first recognition site and a corresponding cleavage site, wherein the first recognition site overlaps with a methylation site that forms a boundary between an insertion site component and a backbone component, and (ii) a second recognition site and a corresponding cleavage site, wherein the second recognition site lacks an overlapping methylation site.
[0049] In some embodiments, the cleavage site corresponding to the first recognition site and the cleavage site corresponding to the second recognition site of the double restriction enzyme cutting site are separated from each other by at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25 at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 nucleotides.
[0050] In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction site or the 3' IIS type double restriction site are separated by at least one nucleotide. In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction site and the 3' IIS type double restriction site are separated from each other by at least one nucleotide.
[0051] In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction enzyme cleavage site and the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 3' IIS type double restriction enzyme cleavage site are separated by the same nucleotide sequence (i.e., the same nucleotide sequence).
[0052] In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5'IIS type double restriction enzyme site and the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 3'IIS type double restriction enzyme site are separated by different nucleotide sequences. The identity of one or more nucleotides of different nucleotide sequences may be different. In some embodiments, the different nucleotide sequences are the same length. In other embodiments, the lengths of different nucleotide sequences are different.
[0053] In some embodiments, the cleavage site corresponding to the first recognition site and the cleavage site corresponding to the second recognition site of the double restriction enzyme cutting site include a shared cleavage site (i.e., the IIS type restriction endonuclease that binds to the first recognition site and the IIS type restriction endonuclease that binds to the second recognition site cut the same cleavage site). In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5'IIS type double restriction enzyme cutting site or the 3'IIS type double restriction enzyme cutting site include a shared cleavage site. In some embodiments, the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5'IIS type double restriction enzyme cutting site and the 3'IIS type double restriction enzyme cutting site include a shared cleavage site.
[0054] In some embodiments, the cleavage site corresponding to the first recognition site and the cleavage site corresponding to the second recognition site are the same (even though the cleavage sites are not shared).
[0055] In some embodiments, the cleavage site corresponding to the first recognition site and the cleavage site corresponding to the second recognition site have different nucleotide sequences.
[0056] In some embodiments, the cleavage site corresponding to the first recognition site and the cleavage site corresponding to the second recognition site have different nucleotide lengths. In some embodiments, the cleavage site corresponding to the first recognition site and / or the cleavage site corresponding to the second recognition site of the 5' IIS type double restriction enzyme cleavage site have different lengths than the first recognition site and / or the second recognition site of the 3' IIS type double restriction enzyme cleavage site.
[0057] In some embodiments, the 5' Type IIS double restriction site and the 3' Type IIS double restriction site of the insertion site component are separated by at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 2000, or at least 5000 nucleotides. In some embodiments, the nucleic acid sequence separating the 5' IIS type double restriction site and the 3' IIS type double restriction site comprises a counter selection marker (e.g., sacB, rpsL (strA), tatAR, pheS, thyA, lacY, lacZ, gata-1, ccdb, galK, or ePheSA294G). In some embodiments, the counter selection marker is a visual readout marker or a suicide cassette (i.e., a lethal counter selection tag). In some embodiments, the visual readout marker is selected from the group consisting of: a fluorescent protein or LacZ. In some embodiments, the suicide cassette comprises the nucleic acid sequence of ccdB.
[0058] In some embodiments, at least one Type IIS restriction site in the backbone component is different in nucleotide sequence from at least one Type IIS restriction site in the insert component.
[0059] In some embodiments, at least one cleavage site corresponding to a common recognition site in a backbone component is different from the nucleotide sequence of at least one cleavage site corresponding to a common recognition site in an insert component. In some embodiments, each cleavage site corresponding to a common recognition site in a backbone component is different from the nucleotide sequence of each cleavage site corresponding to a common recognition site in an insert component. In some embodiments, each cleavage site corresponding to a common recognition site in a destination vector is unique.
[0060] In some embodiments, the methylation site of each common recognition site overlapping with the methylation site in the destination vector is the same (that is, each methylation site overlapping with the common recognition site in the destination vector can be methylated by the same methyltransferase). In some embodiments, the methylation site of at least two common recognition sites overlapping with the methylation site in the destination vector is unique (that is, at least two methylation sites overlapping with the common recognition site in the destination vector are methylated by different methyltransferases). Examples of methyltransferases include, but are not limited to, CpG methyltransferases (optionally M.SssI), dam methyltransferases, dcm methyltransferases, GpC methyltransferases (optionally M.CviPI), AluI methyltransferases, BamHI methyltransferases, EcoRI methyltransferases, HaeIII methyltransferases, HhaI methyltransferases, HpaII methyltransferases, MspI methyltransferases, and TaqI methyltransferases.
[0061] Figure 1 A schematic diagram of an embodiment of a destination vector is provided. In this embodiment, 5'IIS type double restriction enzyme cutting site and 3'IIS type double restriction enzyme cutting site each include the first common recognition site and the second common recognition site overlapping with the methylation site. In this case, the common recognition site is the recognition site of BsaI. The BsaI restriction enzyme cutting site includes the recognition site of 5'-GGTCTC-3' and the cleavage site of (N1) / (N5) (i.e. 5'-NNNNNN-3', wherein N represents A, T, G or C, and generates the 5' overhang of four base pairs when cutting). In this case, the cleavage site of the first common recognition site and the second common recognition site is a shared cleavage site. It will be appreciated by those skilled in the art that the nucleotide sequence of the shared cleavage site of the 5'IIS type double restriction enzyme cutting site and the nucleotide sequence of the shared cleavage site of the 3'IIS type double restriction enzyme cutting site may be different from each other. It will also be appreciated by those skilled in the art that the BsaI common recognition site (and its corresponding cleavage site) can be replaced by any other IIS type restriction endonuclease recognition site. Moreover, it will be appreciated by those skilled in the art that the cleavage site of the first common recognition site of the 5'IIS type double restriction enzyme site and / or the cleavage site of the second common recognition site of the 3'IIS type double restriction enzyme site need not be a shared cleavage site. In addition, this embodiment depicts an MspI methylation site that overlaps with the BsaI recognition site. It will be appreciated by those skilled in the art that the MspI methylation site can be replaced by any other methylation site known in the art.
[0062] In some embodiments, when methylated, the target vector is exposed to a Type IIS restriction endonuclease that recognizes a common recognition site of the target vector to generate at least two polynucleic acid fragments, wherein the nucleotide sequence of the 5' nucleic acid overhang or the 3' nucleic acid overhang of the fragment including the backbone component is different.
[0063] In some embodiments, when unmethylated, exposing the target vector to a Type IIS restriction endonuclease that recognizes a common recognition site of the target vector generates at least three polynucleic acid fragments, wherein each polynucleic acid includes a 5' nucleic acid overhang or a 3' nucleic acid overhang, and the nucleotide sequences of the 5' nucleic acid overhang or the 3' nucleic acid overhang of the fragments including the second common recognition sequence of both the 5' Type IIS double restriction enzyme site and the 3' Type IIS double restriction enzyme site are different.
[0064] In some embodiments, a polynucleic acid destination vector comprises a backbone component and an insertion site component, wherein: (a) the backbone component comprises a nucleic acid sequence of a selectable marker, an origin of replication, and at least one Type IIS restriction site comprising a common recognition site and a corresponding cleavage site, wherein the common recognition site overlaps with a methylation site; and (b) the insertion site component comprises a 5' Type IIS double restriction site and a 3' Type IIS double restriction site, optionally wherein the 5' Type IIS double restriction site and the 3' Type IIS double restriction site are separated by at least one nucleotide; wherein each Type IIS double restriction site comprises: (i) a first common recognition site and a corresponding cleavage site, wherein the first common recognition site overlaps with a methylation site forming a boundary between the insertion site component and the backbone component, and (ii) a second common recognition site and a corresponding cleavage site, wherein the second recognition site lacks an overlapping methylation site, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site are both located between the first common recognition site and the second common recognition site, wherein: methylation of the target vector at the common recognition site overlapping with the methylation site hinders cleavage of the cleavage site corresponding to the common recognition site; when methylated, the target vector is exposed to an IIS type restriction endonuclease that recognizes the common recognition site of the target vector, generating two polynucleic acid fragments, wherein the nucleotide sequences of the 5' end nucleic acid protrusion or the 3' end nucleic acid protrusion of the fragment including the backbone component are different; and the nucleotide sequence of the IIS type cleavage site in (a) is different from that of the IIS type cleavage site in (b).
[0065] Access vectors and compositions
[0066] In some aspects, the disclosure relates to entry vector polynucleic acids including entry vector polynucleic acids and compositions including. In some embodiments, the entry vector is a linear vector. In other embodiments, the entry vector is a circular vector. The entry vector includes a backbone component (as described above in "Destination Vectors and Compositions") and an insert component.
[0067] As used herein, the term "insertion sequence component" refers to a polynucleic acid comprising a first Type IIS restriction site, an insertion sequence, and a second Type IIS restriction site (see, e.g., Figure 2 ). As used herein, the term "insert sequence" refers to a nucleic acid sequence flanked by a first Type IIS restriction site and a second Type IIS restriction site. The nucleotide length of the insert sequence may vary. For example, the length of the insert sequence may be at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 2000, at least 5000, at least 10,000, or at least 20,000 nucleotides.
[0068] In some embodiments, the first Type IIS restriction site and the second Type IIS restriction site of the insertion component are inwardly facing (i.e., the cleavage sites corresponding to the first recognition site and the second recognition site are located between the two recognition sites). In some embodiments, the recognition site of the first Type IIS restriction site and the recognition site of the second Type IIS restriction site are both common recognition sites.
[0069] In some embodiments, the cleavage site of the first Type IIS restriction site of the inserted component and the cleavage site of the second Type IIS restriction site of the inserted component have different nucleotide sequences.
[0070] In some embodiments, in addition to the sequence of the cleavage site, the nucleic acid sequence of the first restriction site is the reverse complementary sequence of the second restriction site. For example, in some embodiments, the nucleic acid sequence of the first Type IIS restriction site is CCGGTCTCNNNNNN (SEQ ID NO: 3), and the nucleic acid sequence of the second Type IIS restriction site is NNNNNGAGACCGG (SEQ ID NO: 4), wherein N represents A, T, G or C.
[0071] In some embodiments, at least one Type IIS restriction site in a backbone component of an incoming vector is different in nucleotide sequence from at least one Type IIS restriction site in an insert component of an incoming vector.
[0072] In some embodiments, at least one cleavage site corresponding to a common recognition site in a backbone component and at least one cleavage site corresponding to a common recognition site in an inserted component have different nucleotide sequences. In some embodiments, each cleavage site corresponding to a common recognition site in a backbone component and each cleavage site corresponding to a common recognition site in an inserted component have different nucleotide sequences. In some embodiments, each cleavage site corresponding to a common recognition site is unique.
[0073] In some embodiments, the methylation site of each common recognition site that overlaps with a methylation site in the entry vector is the same (i.e., each methylation site that overlaps with a common recognition site in the destination vector can be methylated by the same methyltransferase). In some embodiments, the methylation sites of at least two common recognition sites that overlap with a methylation site in the entry vector are unique (i.e., at least two methylation sites that overlap with a common recognition site in the destination vector are methylated by different methyltransferases).
[0074] In some embodiments, methylation of the entry vector at a consensus recognition site that overlaps with a methylation site blocks cleavage at the cleavage site corresponding to the consensus recognition site.
[0075] In some embodiments, when unmethylated, exposure of the entry vector to a Type IIS restriction endonuclease that recognizes a common recognition site of the entry vector generates at least two polynucleic acid fragments, wherein each polynucleic acid fragment comprises a 5' terminal nucleic acid overhang or a 3' terminal nucleic acid overhang, and wherein one of the at least two polynucleic acid fragments comprises an insert sequence of the entry vector. In some embodiments, the nucleotide sequences of the 5' overhang or the 3' overhang of the polynucleic acid fragments comprising the insert sequence are different.
[0076] In some embodiments, the polynucleic acid entry vector comprises a backbone component and an insert component, wherein (a) the backbone component comprises a backbone component of a polynucleic acid destination vector as disclosed herein; and (b) the insert component comprises, from 5' to 3', a first Type IIS restriction site, an insert sequence, and a second Type IIS restriction site; wherein the first Type IIS restriction site and the second Type IIS restriction site each comprise: (i) a common recognition site overlapping with a methylation site, wherein the methylation site forms a boundary between the insert component and the backbone component, and (ii) a corresponding cleavage site, wherein cleavage of the cleavage site of the first Type IIS restriction site and the second Type IIS restriction site generates a 5' overhang or a 3' overhang, wherein the nucleotide sequences of the 5' overhang or the 3' overhang of the first Type IIS restriction site and the 5' overhang or the 3' overhang of the second Type IIS restriction site are different from each other.
[0077] Figure 2A schematic diagram of an embodiment of an entry vector is provided. In this embodiment, the first IIS type restriction enzyme cutting site and the second IIS type double restriction enzyme cutting site each include a common recognition site overlapping with a methylation site. In this case, the common recognition site is the recognition site of BsaI. The BsaI restriction enzyme cutting site includes a recognition site of 5'-GGTCTC-3' and a cleavage site of (N1) / (N5) (i.e. 5'-NNNNNN-3', wherein N represents A, T, G or C, and generates a 5' overhang of four base pairs when cutting). It will be appreciated by those skilled in the art that the BsaI common recognition site (and its corresponding cleavage site) can be replaced by any other IIS type restriction endonuclease recognition site. Moreover, it will be appreciated by those skilled in the art that the cleavage site of the first IIS type restriction enzyme cutting site and the cleavage site of the second IIS type restriction enzyme cutting site need not be identical. In addition, this embodiment depicts an MspI methylation site overlapping with the BsaI recognition site. It will be appreciated by those skilled in the art that the MspI methylation site can be replaced by any number of methylation sites known in the art.
[0078] Composition of a kit for assembling polynucleic acids having a predetermined sequence
[0079] In some aspects, the present disclosure relates to a composition of a kit for assembling a polynucleic acid having a predetermined sequence. In some embodiments, the kit includes a kit of destination vectors, as described above in "Destination vectors and compositions", wherein: (i) the 5'-type IIS double restriction site of each destination vector in the kit of destination vectors has a different nucleotide sequence from the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the first recognition site of the 3'-type IIS double restriction site; (ii) the cleavage site of the 5'-type IIS double restriction site of at least one destination vector in the kit of destination vectors is the same as the 3'-type IIS double restriction site of at least one other destination vector in the kit of destination vectors; and (iii) the cleavage site of the 3'-type IIS double restriction site of at least one destination vector in the kit of destination vectors is the same as the 5'-type IIS double restriction site of at least one other destination vector in the kit of destination vectors.
[0080] In some embodiments, each destination vector in the kit of destination vectors comprises a backbone component and an insertion site component, wherein: (a) the backbone component comprises a nucleic acid sequence of a selectable marker, an origin of replication, and at least one Type IIS restriction site comprising a common recognition site and a corresponding cleavage site, wherein the common recognition site overlaps with a methylation site; and (b) the insertion site component comprises a 5' Type IIS double restriction site and a 3' Type IIS double restriction site, optionally wherein the 5' Type IIS double restriction site and the 3' Type IIS double restriction site are separated by at least one nucleotide; wherein each Type IIS double restriction site comprises: (i) a first common recognition site and a corresponding cleavage site, wherein the first common recognition site overlaps with a methylation site forming a boundary between the insertion site component and the backbone component, and (ii) a second common recognition site and a corresponding cleavage site, wherein the second recognition site lacks an overlapping methylation site, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site are both located between the first common recognition site and the second common recognition site, wherein: methylation of the target vector at the common recognition site overlapping with the methylation site hinders cleavage of the cleavage site corresponding to the common recognition site; when methylated, the target vector is exposed to a Type IIS restriction endonuclease that recognizes the common recognition site of the target vector, generating two polynucleic acid fragments, wherein the nucleotide sequence of the 5' nucleic acid overhang or the 3' nucleic acid overhang of the fragment including the backbone component is different; and the Type IIS cleavage site in (a) is different from the nucleotide sequence of the Type IIS cleavage site in (b).
[0081] In some embodiments, the kit of destination vectors comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 20, at least 25, at least 30, at least 40, at least 50 or more than 50 different destination vectors. In some embodiments, each destination vector in the kit of destination vectors comprises the same backbone components. In some embodiments, at least one destination vector in the kit of destination vectors comprises a unique backbone component.
[0082] In some embodiments, the kit further comprises at least one reaction buffer (e.g., a digestion buffer, a ligase buffer, a methyltransferase buffer, and / or a universal buffer), at least one type IIS restriction endonuclease (e.g., AlwI, BbsI, BceAI, BcgI, BcoDI, BfuAI, BsaI, BsmAI, BsmBI, BsmFI, BtgZI, EarI, EciI, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, MboII, MmeI, PleI, I, SapI, SfaNI and / or functional variants thereof), at least one methyltransferase (e.g., CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, TaqI methyltransferase and / or functional variants thereof), at least one ligase (e.g., T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Escherichia coli DNA ligase, taq DNA ligase and / or functional variants thereof), and / or a preparation of at least one competent cell.
[0083] In some embodiments, the kit includes at least two preparations of competent cells, wherein at least one preparation of competent cells includes cells expressing a methyltransferase capable of methylating the target vector at a methylation site overlapping the common recognition site, and wherein at least one preparation of competent cells includes cells that cannot methylate the target vector at a methylation site overlapping the common recognition site. In some embodiments, the competent cells are prokaryotic cells. In some embodiments, the competent cells are eukaryotic cells.
[0084] Method for assembling polynucleic acids having predetermined sequences
[0085] In some aspects, the present disclosure relates to a method for assembling a polynucleic acid with a predetermined sequence. In some embodiments, the method for assembling a polynucleic acid with a predetermined sequence includes forming a first reaction mixture, wherein the first reaction mixture includes at least two polynucleic acids and a type IIS restriction endonuclease, wherein the formation of the first reaction mixture generates at least two polynucleic acid cleavage products including a 5' overhang or a 3' overhang, and wherein the at least two polynucleic acid cleavage products together include a polynucleic acid with a predetermined sequence. In some embodiments, the method further includes forming a second reaction mixture, wherein the second reaction mixture includes at least two polynucleic acid cleavage products and a ligase, wherein the 5' overhang or 3' overhang of the at least two polynucleic acid cleavage products are uniquely complementary to each other so as to form a predetermined sequence by connection.
[0086] In some embodiments, the first reaction mixture and the second reaction mixture are formed sequentially (i.e., a reaction mixture comprising a Type IIS restriction endonuclease is formed first, followed by a reaction mixture comprising a ligase). In some embodiments, at least two polynucleic acid cleavage products are purified prior to forming the second reaction mixture. In some embodiments, the first reaction mixture and the second reaction mixture are identical (i.e., cleavage and ligation of the destination vector and entry vector occur in a single reaction volume).
[0087] In some embodiments, the at least two polynucleic acids of the first reaction mixture include a destination vector as described above in "Destination Vectors and Compositions", and at least one entry vector as described above in "Entry Vectors and Compositions". For example, in some embodiments, the method includes: (a) forming a reaction mixture by combining: (i) a destination vector, wherein the methylation sites of both the backbone component and the insertion site component of the destination vector are methylated; (ii) at least one entry vector, wherein the methylation sites of the backbone component and the insert component of each of the at least one entry vector are unmethylated; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes a common recognition site of the destination vector and the entry vector; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for Type IIS restriction endonuclease-mediated cleavage of the destination vector and the at least one entry vector; and (c) incubating the reaction mixture for a time sufficient for the ligase to ligate the insert sequence of each of the at least one entry vector to the backbone component of the destination vector, thereby generating a circular polynucleic acid; and wherein the 5' overhang or 3' overhang of the backbone component of the destination vector and the insert component of each of the at least one entry vector are uniquely complementary to each other so as to form a predetermined sequence comprising the backbone component of the destination vector of step (a)(i) and the insert component of each of the at least one entry vector of step (a)(ii).
[0088] In some embodiments, the first reaction mixture includes at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more than 10 entry supports.
[0089] In some embodiments, the destination vector is methylated in vitro (e.g., by forming a reaction mixture comprising the destination vector and a methyltransferase and incubating the reaction mixture for a sufficient time for the methyltransferase to methylate the destination vector). In other embodiments, the destination vector is methylated in vivo. For example, in some embodiments, the destination vector is methylated in a bacterial strain of an expressed methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
[0090] In some embodiments, the method further comprises isolating the ligated destination vector containing the insert sequence from the other components of the reaction mixture. In some embodiments, the ligated destination vector is isolated by transforming bacteria with the second reaction mixture and screening the bacteria for the presence of correctly ligated assemblies.
[0091] In some embodiments, method further comprises the demethylation of the connection destination vector of separation, to generate the second entry vector.In some embodiments, the connection destination vector of separation is passively demethylated.For example, the destination vector can be passively demethylated through in vitro amplification (for example, PCR).Alternatively, the destination vector can be passively demethylated in vivo by duplicating in the bacterial strain lacking a methyltransferase, and the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase and TaqI methyltransferase.
[0092] In some embodiments, the backbone of the destination vector is identical to the backbone of at least one entry vector. In some embodiments, the backbone of the destination vector is identical to the backbone of each entry vector.
[0093] Figure 3Provide a schematic diagram depicting an embodiment, wherein the at least two polynucleic acids of the first reaction mixture include a destination vector as described above and at least one entry vector as described above. It will be appreciated by those skilled in the art that the depicted method can be modified by using different destination vectors and / or entry vectors.
[0094] In other embodiments, the at least two polynucleic acids of the first reaction mixture include a destination vector as described above in "Destination vectors and compositions", and at least one polynucleic acid fragment (e.g., a PCR product or other synthetic fragment). For example, in some embodiments, the method includes: (a) forming a reaction mixture by combining: (i) a destination vector, wherein the methylation site of the backbone component is methylated; (ii) at least one polynucleic acid fragment, wherein each polynucleic acid fragment includes an internal sequence flanked at both ends by a common recognition site and a corresponding cleavage site;
[0095] (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes a common recognition site of the target vector and the at least one polynucleic acid fragment; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for the Type IIS restriction endonuclease-mediated cleavage of the target vector and the at least one polynucleic acid fragment; and (c) incubating the reaction mixture for a time sufficient for the ligase to ligate the insert sequence of each of the at least one polynucleic acid fragment to the backbone component of the target vector, thereby generating a circular polynucleic acid; and wherein the internal sequence of at least one polynucleic acid fragment includes a nucleic acid sequence of interest; and wherein the 5' overhang or 3' overhang of the backbone component of the target vector and the internal sequence of each of the at least one polynucleic acid fragment are uniquely complementary to each other so as to form a predetermined sequence comprising the backbone component of the target vector of step (a)(i) and the nucleic acid sequence of interest.
[0096] In some embodiments, the destination vector is methylated in vitro (for example, by forming a reaction mixture comprising the destination vector and a methyltransferase and incubating the reaction mixture for a time sufficient for the methyltransferase to methylate the destination vector). In other embodiments, the destination vector is methylated in vivo. For example, in some embodiments, the destination vector is methylated in a bacterial strain of an expressed methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
[0097] In some embodiments, the method further comprises separating the ligated destination vector containing the insert sequence from the other components of the second reaction mixture. In some embodiments, the ligated destination vector is separated by transforming cells (e.g., bacteria) with the second reaction mixture and screening cells or cell progeny for the presence of the correctly ligated assembly.
[0098] In some embodiments, the method further comprises demethylating the separated ligated destination vector to generate a second entry vector. In some embodiments, the separated ligated destination vector is replicated in a bacterial strain lacking a methyltransferase and passively demethylated in vivo, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase (optionally M.SssI), dam methyltransferase, dcm methyltransferase, GpC methyltransferase (optionally M.CviPI), AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
[0099] In other embodiments, the at least two polynucleic acids of the first reaction mixture include an entry vector and a polynucleic acid fragment (eg, a PCR product or other synthetic fragment) as described above in "Entry Vectors and Compositions." For example, in some embodiments, the method includes: (a) forming a reaction mixture by combining the following: (i) at least one entry vector as disclosed herein, wherein the methylation sites of the backbone component are unmethylated; (ii) polynucleic acid fragments, wherein the polynucleic acid fragments include internal sequences, wherein the internal sequences are flanked at both ends by a common recognition site and a corresponding cleavage site; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes the common recognition site of the at least one entry vector and the polynucleic acid fragment; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for the Type IIS restriction endonuclease-mediated cleavage of the at least one entry vector and the polynucleic acid fragment; and (c) incubating the reaction mixture for a time sufficient for the ligase to connect the internal nucleic acid sequence of the polynucleic acid fragment to the insertion component of each of the at least one entry vector, thereby generating a circular polynucleic acid; and wherein the internal sequence of the polynucleic acid fragment includes a selection marker and an origin of replication; and wherein the 5' overhang or 3' overhang of the insertion component of each of the at least one entry vector and the internal sequence of the at least one polynucleic acid fragment are uniquely complementary to each other so as to form a predetermined sequence including the nucleic acid sequence of interest.
[0100] In some embodiments, the first reaction mixture comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more than 10 entry supports.
[0101] In some embodiments, the backbone of each entry vector is identical.
[0102] In some embodiments, the polynucleic acid fragment comprises a sequence of a backbone component of a destination vector or entry vector as described above. In some embodiments, the polynucleic acid fragment is methylated in vitro.
[0103] In some embodiments, the predetermined sequence further comprises a sequence entering the vector.
[0104] Other Implementations
[0105] All features disclosed in this specification can be combined in any combination. Each feature disclosed in this specification can be replaced by an optional feature for the same, equivalent or similar purpose. Therefore, unless otherwise explicitly stated, each feature disclosed is only an example of a general series of equivalent or similar features.
[0106] From the above description, those skilled in the art can easily determine the essential characteristics of the present disclosure, and without departing from the spirit and scope of the present disclosure, various changes and modifications can be made to the present disclosure to adapt it to various uses and conditions. Therefore, other embodiments are also within the claims.
[0107] Equivalent solutions
[0108] Although several inventive embodiments have been described and illustrated herein, a person skilled in the art will readily appreciate various other means and / or structures for performing the functions described herein and / or obtaining the results and / or one or more advantages, and each of these changes and / or modifications is considered to be within the scope of the inventive embodiments described herein. More generally, a person skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are intended to be exemplary and that the actual parameters, dimensions, materials, and / or configurations will depend on the specific application or application using the teachings of the present invention. A person skilled in the art will recognize or be able to determine many equivalents of the specific inventive embodiments described herein using only routine experiments. Therefore, it should be understood that the foregoing embodiments are presented only by way of example, and within the scope of the appended claims and their equivalents, embodiments of the present invention may be practiced in a manner different from that specifically described and claimed. The inventive embodiments of the present disclosure relate to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually contradictory, is included within the scope of the invention disclosed herein.
[0109] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.
[0110] All references, patents, and patent applications disclosed herein are incorporated by reference for each subject matter cited, and in some cases may be incorporated by reference in their entirety.
[0111] The indefinite articles "a" and "an" as used in the specification and claims should be understood to mean "at least one" unless explicitly indicated to the contrary.
[0112] The phrase "and / or" used in the specification and claims should be understood to mean "one or both" of the elements so combined, that is, elements that appear combined in some cases and separately in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, that is, "one or more" of the elements so connected. In addition to the elements specifically identified by the "and / or" clause, other elements may optionally be present, whether related or unrelated to those specifically identified elements. Thus, as a non-limiting example, when used in conjunction with open language such as "comprising", a reference to "A and / or B" may refer to only A (optionally including elements other than B) in one embodiment; to only B (optionally including elements other than A) in another embodiment; to both A and B (optionally including other elements) in still another embodiment; and so on.
[0113] As used herein in the specification and claims, "or" shall be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive, i.e., including at least one, but also multiple elements in a number of elements or lists of elements, and, optionally, including additional unlisted items. Only when terms are explicitly indicated to the contrary, such as "only one of" or "on one of", or when used in the claims, "consisting of" will mean including only one element in a plurality of elements or a list of elements. In general, the term "or" as used herein, when preceding an exclusive term, such as "either", "one of", "only one of" or "on one of", shall only be interpreted as indicating an exclusive alternative (i.e., "one or the other but not both") . When used in the claims, "consisting essentially of" shall have the ordinary meaning in the field of patent law.
[0114] As used herein in the specification and claims, the phrase "at least one" with respect to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows that elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers may optionally be present, whether related or unrelated to those specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or equivalently, "at least one of A or B", or equivalently "at least one of A and / or B") may refer to at least one, optionally including more than one A, without B (and optionally including elements other than B), in one embodiment; may refer to at least one, optionally including more than one B, without A (and optionally including elements other than A), in another embodiment; may refer to at least one, optionally including more than one A, and at least one, optionally including more than one B (and optionally including other elements), in yet another embodiment; and so on.
[0115] It should also be understood that in any method claimed herein that includes more than one step or action, the order of the method steps or actions is not necessarily limited to the order of the method steps or actions recited unless explicitly stated to the contrary.
[0116] In the claims and the description above, all transitional phrases, such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like, shall be understood to be open ended, i.e., meaning including, but not limited to. As described in Section 2111.03 of the U.S. Patent Office Manual of Patent Examining Procedures, only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively. It shall be understood that, in alternative embodiments, embodiments described in this document using open transitional phrases (e.g., "comprising") are also contemplated as "consisting of the features described by the open transitional phrase" and "consisting essentially of the features described by the open transitional phrase." For example, if the present disclosure describes a "composition comprising A and B," the present disclosure also contemplates the alternative embodiments of "composition consisting of A and B" and "composition consisting essentially of A and B."
Claims
1. A polynucleic acid destination vector comprising a backbone component and an insertion site component, wherein: (a) the backbone components include a nucleic acid sequence of a selectable marker, an origin of replication, and at least one IIS type restriction enzyme cleavage site including a common recognition site and a corresponding cleavage site, wherein the common recognition site overlaps with a methylation site; and (b) the insertion site component includes a 5' IIS type double restriction enzyme site and a 3' IIS type double restriction enzyme site; wherein each Type IIS double restriction enzyme cleavage site comprises: (i) a first common recognition site and a corresponding cleavage site, wherein the first common recognition site overlaps with a methylation site that forms a boundary between the insertion site component and the backbone component, and (ii) a second common recognition site and a corresponding cleavage site, wherein the second recognition site lacks an overlapping methylation site, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site are both located between the first common recognition site and the second common recognition site, wherein: Methylation of the destination vector at a common recognition site that overlaps with a methylation site prevents cleavage of the cleavage site corresponding to the common recognition site; When methylated, exposing the destination vector to a Type IIS restriction endonuclease that recognizes the common recognition site of the destination vector generates two polynucleic acid fragments, wherein the nucleotide sequence of the 5' nucleic acid overhang or the 3' nucleic acid overhang of the fragment including the backbone component is different; and The IIS type cleavage site in (a) and the IIS type cleavage site in (b) have different nucleotide sequences.
2. The destination vector according to claim 1, wherein in (b), the 5' IIS type double restriction site and the 3' IIS type double restriction site are separated by at least one nucleotide.
3. The destination vector according to claim 1 or claim 2, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5'IIS type double restriction site or the 3'IIS type double restriction site are separated from each other by at least one nucleotide.
4. The destination vector according to claim 1 or claim 2, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction enzyme cleavage site and the 3' IIS type double restriction enzyme cleavage site are separated from each other by at least one nucleotide.
5. The destination vector according to claim 4, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5'IIS type double restriction enzyme cleavage site and the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 3'IIS type double restriction enzyme cleavage site are separated from each other by different nucleotide sequences.
6. The destination vector of claim 4, wherein the different nucleotide sequences comprise different nucleic acid lengths.
7. The destination vector according to claim 4, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5'IIS type double restriction enzyme cleavage site and the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 3'IIS type double restriction enzyme cleavage site are separated from each other by the same nucleotide sequence.
8. The destination vector according to claim 1 or claim 2, wherein the cleavage site corresponding to the first common recognition site and the cleavage site corresponding to the second common recognition site of the 5' IIS type double restriction enzyme cleavage site and / or the 3' IIS type double restriction enzyme cleavage site are shared cleavage sites.
9. The destination vector of claim 1 or claim 2, wherein the 5' IIS type double restriction site and the 3' IIS type double restriction site are separated by a nucleic acid sequence encoding a visual readout marker or a suicide cassette.
10. The destination vector of claim 9, wherein the visual readout marker is selected from the group consisting of a fluorescent protein, a chromogenic protein, LacZ or LacZα.
11. The destination vector of claim 9, wherein the suicide box comprises a nucleic acid sequence of ccdB.
12. according to claim 1 or the described destination vector of claim 2, wherein the IIS type restriction endonuclease that binds to described common recognition site is selected from the group consisting of: BsaI, BsmBI, BtgZI, Esp3I, FokI, HphI, BcgI, AlwI, MboII, MmeI, BsmFI, BceAI, BcoDI, BfuAI, BsmAI, EarI, EciI, FauI, HgaI, HpyAV, PleI, BbsI, SapI and SfaNI.
13. The destination vector according to claim 1 or claim 2, wherein at least one type IIS restriction enzyme cleavage site in the backbone component of (a) is located within or flanking the selection marker or the replication origin.
14. The destination vector according to claim 1 or claim 2, wherein the cleavage site of at least one type IIS restriction enzyme cleavage site in the backbone component of (a) comprises a low ligation efficiency sequence content.
15. The destination vector of claim 1 or claim 2, wherein the selection marker comprises an antibiotic resistance gene.
16. The destination vector according to claim 1 or claim 2, wherein the methylation sites of (a) and (b) are methylated by the same methyltransferase.
17. The destination vector of claim 16, wherein the methyltransferase is selected from the group consisting of CpG methyltransferase, dam methyltransferase, dcm methyltransferase, GpC methyltransferase, AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
18. The destination vector of claim 17, wherein the CpG methyltransferase is M.SssI.
19. The destination vector of claim 17, wherein the GpC methyltransferase is M.CviPI.
20. The destination vector according to claim 1 or claim 2, wherein when unmethylated, exposing the destination vector to an IIS type restriction endonuclease that recognizes the common recognition site of the destination vector generates at least three polynucleic acid fragments, wherein each polynucleic acid includes a 5' nucleic acid protrusion or a 3' nucleic acid protrusion, and the nucleotide sequences of the 5' nucleic acid protrusion or the 3' nucleic acid protrusion of the fragments of the second common recognition sequence including both the 5' IIS type double restriction enzyme site and the 3' IIS type double restriction enzyme site are different.
21. A polynucleic acid entry vector comprising a backbone component and an insertion component, wherein: (a) the backbone components include the backbone components of the multi-nucleic acid target vector according to any one of claims 1-20; and (b) the insertion component includes, from 5' to 3', a first Type IIS restriction site, an insertion sequence, and a second Type IIS restriction site; wherein the first Type IIS restriction site and the second Type IIS restriction site each include: (i) a common recognition site overlapping with a methylation site, wherein the methylation site forms a boundary between the insertion component and the backbone component, and (ii) a corresponding cleavage site, wherein cleavage of the cleavage sites of the first Type IIS restriction site and the second Type IIS restriction site generates a 5' overhang or a 3' overhang, wherein the nucleotide sequences of the 5' overhang or the 3' overhang of the first Type IIS restriction site and the 5' overhang or the 3' overhang of the second Type IIS restriction site are different from each other.
22. The entry vector of claim 21, wherein the insert sequence is a nucleic acid sequence that is assembled in an assembly reaction.
23. A method for assembling polynucleic acids into a predetermined sequence, the method comprising: (a) forming a reaction mixture by combining: (i) a destination vector according to any one of claims 1-20, wherein the methylation sites of both the backbone component and the insertion site component of the destination vector are methylated; (ii) at least one entry vector according to any one of claims 21-22, wherein the methylation sites of the backbone component and the insertion component of each of the at least one entry vector are unmethylated; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes the common recognition site of the destination vector and the entry vector; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for Type IIS restriction endonuclease-mediated cleavage of the destination vector and the at least one entry vector; (c) incubating the reaction mixture for a time sufficient for the ligase to ligate the insert sequence of each of the at least one entry vector to the backbone component of the destination vector, thereby generating a circular polynucleic acid; and wherein the 5' overhang or the 3' overhang of the backbone component of the destination vector and the inserted component of each of the at least one entry vector are uniquely complementary to each other so as to form a predetermined sequence comprising the backbone component of the destination vector of step (a)(i) and the inserted component of each of the at least one entry vector of step (a)(ii).
24. The method of claim 23, wherein the destination vector is methylated in vitro.
25. The method of claim 23, wherein the destination vector is methylated in vivo.
26. The method of claim 25, wherein the destination vector is methylated in a bacterial strain expressing a methyltransferase selected from the group consisting of CpG methyltransferase, dam methyltransferase, dcm methyltransferase, GpC methyltransferase, AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
27. The method of claim 26, wherein the CpG methyltransferase is M.SssI.
28. The method of claim 26, wherein the GpC methyltransferase is M.CviPI.
29. The method of any one of claims 23-26, further comprising separating the ligated destination vector containing the insert sequence from other components of the reaction mixture.
30. The method of claim 29, wherein the ligated destination vector is isolated by transforming bacteria with the reaction mixture and screening the bacteria for the presence of a correctly ligated assembly.
31. The method of any one of claims 23-26, further comprising demethylating the separated ligated destination vector to generate a second entry vector.
32. The method of claim 31, wherein the isolated, ligated destination vector is passively demethylated by replication in a bacterial strain lacking a methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase, dam methyltransferase, dcm methyltransferase, GpC methyltransferase, AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
33. The method of claim 32, wherein the CpG methyltransferase is M.SssI.
34. The method of claim 32, wherein the GpC methyltransferase is M.CviPI.
35. A method for cloning a nucleic acid sequence of interest, the method comprising: (a) forming a reaction mixture by combining: (i) a destination vector according to any one of claims 1 to 20, wherein the methylation site of the backbone component is methylated; (ii) at least one polynucleic acid fragment, wherein each polynucleic acid fragment comprises an internal sequence, wherein the internal sequence is flanked at both ends by a common recognition site and a corresponding cleavage site; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes the common recognition site of the destination vector and the at least one polynucleic acid fragment; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for Type IIS restriction endonuclease-mediated cleavage of the destination vector and the at least one polynucleic acid fragment; (c) incubating the reaction mixture for a time sufficient for the ligase to ligate the internal nucleic acid sequence of each of the at least one polynucleic acid fragment to the backbone component of the destination vector, thereby generating a circular polynucleic acid; and wherein said internal sequence of said at least one polynucleic acid fragment comprises a nucleic acid sequence of interest; and wherein the 5' overhang or 3' overhang of the backbone component of the destination vector and the internal sequence of each of the at least one polynucleic acid fragment are uniquely complementary to each other so as to form a predetermined sequence, which comprises the backbone component of the destination vector of step (a)(i) and the nucleic acid sequence of interest.
36. The method of claim 35, wherein the destination vector is methylated in vitro.
37. The method of claim 35, wherein the destination vector is methylated in vivo.
38. The method of claim 37, wherein the destination vector is methylated in a bacterial strain expressing a methyltransferase selected from the group consisting of CpG methyltransferase, dam methyltransferase, dcm methyltransferase, GpC methyltransferase, AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
39. The method of claim 38, wherein the CpG methyltransferase is M.SssI.
40. The method of claim 38, wherein the GpC methyltransferase is M.CviPI.
41. The method of any one of claims 35-40, further comprising separating the ligated destination vector containing the predetermined sequence from the other components of the reaction mixture.
42. The method of claim 41, wherein the ligated destination vector is isolated by transforming bacteria with the reaction mixture and screening the bacteria for the presence of a correctly ligated assembly.
43. The method of any one of claims 35-40, further comprising demethylating the separated ligated destination vector to generate a second entry vector.
44. The method of claim 43, wherein the isolated, ligated destination vector is passively demethylated in vivo by replication in a bacterial strain lacking a methyltransferase, wherein the methyltransferase is selected from the group consisting of: CpG methyltransferase, dam methyltransferase, dcm methyltransferase, GpC methyltransferase, AluI methyltransferase, BamHI methyltransferase, EcoRI methyltransferase, HaeIII methyltransferase, HhaI methyltransferase, HpaII methyltransferase, MspI methyltransferase, and TaqI methyltransferase.
45. The method of claim 44, wherein the CpG methyltransferase is M.SssI.
46. The method of claim 44, wherein the GpC methyltransferase is M.CviPI.
47. A method for cloning a nucleic acid sequence of interest, the method comprising: (a) forming a reaction mixture by combining: (i) at least one entry vector according to any one of claims 21-22, wherein the methylation sites of the backbone components are unmethylated; (ii) a polynucleic acid fragment, wherein the polynucleic acid fragment comprises an internal sequence flanked at both ends by a common recognition site and a corresponding cleavage site; (iii) a Type IIS restriction endonuclease, wherein the Type IIS restriction endonuclease recognizes the common recognition site of the at least one entry vector and the polynucleic acid fragment; and (iv) a ligase; (b) incubating the reaction mixture for a time sufficient for Type IIS restriction endonuclease-mediated cleavage of the at least one entry vector and the polynucleic acid fragment; (c) incubating the reaction mixture for a time sufficient for the ligase to ligate the internal nucleic acid sequence of the polynucleic acid fragment to the insert component of each of the at least one entry vector, thereby generating a circular polynucleic acid; and wherein the internal sequence of the polynucleic acid fragment comprises a selection marker, an origin of replication, and at least one Type IIS restriction site comprising a common recognition site and a corresponding cleavage site, wherein the common recognition site overlaps with a methylation site that is methylated; and The 5' overhang or 3' overhang of the insert component of each of the at least one incoming vector and the internal sequence of the at least one polynucleic acid fragment are uniquely complementary to each other so as to form a predetermined sequence including the nucleic acid sequence of interest.
48. The method of claim 47, wherein the polynucleic acid fragments are PCR products.
49. The method of claim 47 or claim 48, wherein the polynucleic acid fragment is methylated in vitro.
50. The method of claim 47 or claim 48, wherein the predetermined sequence further comprises a sequence entering a vector.
